Physiological basis for the use of erythropoietin in critically ill patients at risk for acute kidney injury

Current Opinion in Critical Care

Volumn 14, Issue 6, 2008, Pages 621-626

  Bernhardt, Wanja M ^a   Eckardt, Kai Uwe ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Acute kidney injury; Erythropoietin; Hypoxia; Hypoxia inducible transcription factor; Ischemia

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CRITICALLY ILL PATIENT; ERYTHROCYTE COUNT; HUMAN; HYPOXIA; INTENSIVE CARE; ISCHEMIA; KIDNEY INJURY; LENGTH OF STAY; MORTALITY; RENAL PROTECTION; REVIEW;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARRIER PROTEINS; CRITICAL ILLNESS; ERYTHROPOIETIN, RECOMBINANT; HEMATOPOIESIS; HUMANS; KIDNEY FAILURE, ACUTE; RISK FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 57149111046     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e328317ee82     Document Type: Review

References (76)

1. Venkataraman R, Kellum JA. Defining acute renal failure: the RIFLE criteria. J Intensive Care Med 2007; 22:187-193.
2. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int 2008; 73:538-546.
3. Liangos O, Perianayagam MC, Vaidya VS, et al. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol 2007; 18:904-912.
4. Ostermann M, Chang RW. Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007; 35:1837-1843.
5. Hoste EA, Clermont G, Kersten A, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006; 10:R73.
6. Oppert M, Engel C, Brunkhorst FM, et al. Acute renal failure in patients with severe sepsis and septic shock: a significant independent risk factor for mortality - results from the German Prevalence Study. Nephrol Dial Transplant 2008; 23:904-909.
7. Bagshaw SM, Mortis G, Doig CJ, et al. One-year mortality in critically ill patients by severity of kidney dysfunction: a population-based assessment. Am J Kidney Dis 2006; 48:402-409.
8. Abuelo JG. Normotensive ischemic acute renal failure. N Engl J Med 2007; 357:797-805.
9. Schrier RW, Wang W, Poole B, Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 2004; 114:5-14.
10. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 2003; 14:2199-2210.
11. Camot P, Deflandre C. About the hematopoietic acitivity of the serum during the regeneration of blood. C R Acad Sci Paris 1906; 143:384-386.
12. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin 1. J Biol Chem 1977; 252:5558-5564.
13. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 1985; 82:7580-7584.
14. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985; 313:806-810.
15. D'Andrea AD, Zon LI. Erythropoietin receptor. Subunit structure and activation. J Clin Invest 1990; 86:681-687.
16. Livnah O, Stura EA, Middleton SA, et al. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 1999; 283:987-990.
17. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999; 283:990-993.
18. Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993; 74:227-236.
19. Tauchi T, Feng GS, Shen R, et al. Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways. J Biol Chem 1995; 270:5631-5635.
20. Jelkmann W. Erythropoietin after a century of research : younger than ever. Eur J Haematol 2007; 78:183-205.
21. Klingmuller U, Lorenz U, Cantley LC, et al. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995; 80:729-738.
22. Bachmann S, Le HM, Eckardt KU. Co-localization of erythropoietin mRNA and ecto-5′-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 1993; 41:335-341.
23. Maxwell PH, Osmond MK, Pugh CW, et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 1993; 44:1149-1162.
24. Eckardt KU, Ratcliffe PJ, Tan CC, et al. Age-dependent expression of the erythropoietin gene in rat liver and kidneys 1. J Clin Invest 1992;89:753-760.
25. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12:5447-5454.
26. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270:1230-1237.
27. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004; 5:343-354.
28. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294:1337-1340.
29. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292:468-472.
30. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999; 55:808-820.
31. Westenfelder C. Unexpected renal actions of erythropoietin. Exp Nephrol 2002; 10:294-298.
32. Anagnostou A, Lee ES, Kessimian N, et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990;87:5978-5982.
33. Bahlmann FH, De GK, Spandau JM, et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004; 103:921-926.
34. Tan CC, Tan LH, Eckardt KU. Erythropoietin production in rats with post-ischemic acute renal failure. Kidney Int 1996; 50:1958-1964.
35. Gong H, Wang W, Kwon TH, et al. EPO and alpha-MSH prevent ischemia/ reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int 2004; 66:683-695.
36. Siren AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001; 98:4044-4049.
37. Nemoto T, Yokota N, Keane WF, Rabb H. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int 2001; 59:246-251.
38. Yang CW, Li C, Jung JY, et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 2003; 17:1754-1755.
39. Vesey DA, Cheung C, Pat B, et al. Erythropoietin protects against ischemic acute renal injury. Nephrol Dial Transplant 2004; 19:348-355.
40. Sharpies EJ, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004; 15:2115-2124.
41. Patel NS, Sharpies EJ, Cuzzocrea S, et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo 8. Kidney Int 2004; 66:983-989.
42. Johnson DW, Pat B, Vesey DA, et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006; 69:1806-1813.
43. Spandou E, Tsouchnikas I, Karkavelas G, et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischemic/reperfusion model. Nephrol Dial Transplant 2006; 21:330-336.
44. Ates E, Yalcin AU, Yilmaz S, et al. Protective effect of erythropoietin on renal ischemia and reperfusion injury. ANZ J Surg 2005; 75:1100-1105.
45. Mitra A, Bansal S, Wang W, et al. Erythropoietin ameliorates renal dysfunction during endotoxaemia. Nephrol Dial Transplant 2007; 22:2349-2353.
46. Abdelrahman M, Sharpies EJ, McDonald MC, et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004; 22:63-69.
47. Bagnis C, Beaufils H, Jacquiaud C, et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 2001; 16:932-938.
48. Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 1994; 266:F360-F366.
49. Baldwin MD, Zhou XJ, Ing TS, Vaziri ND. Erythropoietin ameliorates anemia of cisplatin induced acute renal failure. ASAIO J 1998; 44:44-47.
50. Goldfarb M, Rosenberger C, Ahuva S, et al. A role for erythropoietin in the attenuation of radiocontrast-induced acute renal failure in rats. Ren Fail 2006; 28:345-350.
51. Imamura R, Isaka Y, Ichimaru N, et al. Carbamylated erythropoietin protects the kidneys from ischemia-reperfusion injury without stimulating erythropoiesis. Biochem Biophys Res Commun 2007; 353:786-792.
52. Yokomaku Y, Sugimoto T, Kume S, et al. Asialoerythropoietin prevents contrast-induced nephropathy. J Am Soc Nephrol 2008; 19:321-328.
53. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006; 70:246-250.
54. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005; 6:484-494.
55. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 2004; 101:14907-14912.
56. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003; 102:1340-1346.
57. Wojchowski DM, Gregory RC, Miller CP, et al. Signal transduction in the erythropoietin receptor system. Exp Cell Res 1999; 253:143-156.
58. Eefting F, Rensing B, Wigman J, et al. Role of apoptosis in reperfusion injury. Cardiovasc Res 2004; 61:414-426.
59. Iversen PO, Nicolaysen A, Kvernebo K, et al. Human cytokines modulate arterial vascular tone via endothelial receptors. Pflugers Arch 1999; 439:93-100.
60. Villa P, Bigini P, Mennini T, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003; 198:971-975.
61. Sharpies EJ. Acute kidney injury: stimulation of repair. Curr Opin Crit Care 2007; 13:652-655.
62. Haase VH. Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol 2006; 291:F271-F281.
63. Eckardt KU, Bernhardt W, Willam C, Wiesener M. Hypoxia-inducible transcription factors and their role in renal disease. Semin Nephrol 2007; 27:363-372.
64. Bernhardt WM, Campean V, Kany S, et al. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J Am Soc Nephrol 2006; 17:1970-1978.
65. Rosenberger C, Mandriota S, Jurgensen JS, et al. Expression of hypoxia-inducible factor-1 alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 2002; 13:1721-1732.
66. Hill P, Shukla D, Tran MG, et al. Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol 2008; 19:39-46.
67. Rosenberger C, Rosen S, Shina A, et al. Activation of hypoxia inducible factors (HIF) ameliorates hypoxic distal tubular injury in the isolated perfused rat kidney. Nephrol Dial Transplant 2008 [Epub ahead of print].
68. Weidemann A, Bernhardt WM, Klanke B, et al. HIF activation protects from acute kidney injury. J Am Soc Nephrol 2008; 19:486-494.
69. Matsumoto M, Makino Y, Tanaka T, et al. Induction of renoproteetive gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J Am Soc Nephrol 2003; 14:1825-1832.
70. Bernhardt WM, Warnecke C, Willam C, et al. Organ protection by hypoxia and hypoxia-inducible factors. Methods Enzymol 2007; 435: 221-245.
71. Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002; 17 (Suppl 11):39-43.
72. Georgopoulos D, Matamis D, Routsi C, et al. Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]. Crit Care 2005; 9:R508-R515.
73. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 1999; 27:2346-2350.
74. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357:965-976.
75. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8:495-505.
76. Johnson DW, Forman C, Vesey DA. Novel renoprotective actions of erythropoietin: new uses for an old hormone. Nephrology (Carlton) 2006; 11:306-312.